The use of the Hanks Herbst vs Twin-block in Class II malocclusion: A randomized controlled trial.


Journal

American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics
ISSN: 1097-6752
Titre abrégé: Am J Orthod Dentofacial Orthop
Pays: United States
ID NLM: 8610224

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 01 11 2022
revised: 01 06 2023
accepted: 01 06 2023
medline: 29 8 2023
pubmed: 6 7 2023
entrez: 6 7 2023
Statut: ppublish

Résumé

This 2-arm parallel study aimed to compare and evaluate the efficiency of Hanks Herbst (HH) and Twin-block (TB) functional appliances in treating adolescents with Class II malocclusion. A parallel-group randomized controlled trial was undertaken in a single United Kingdom hospital. Eighty participants were recruited and randomized in a 1:1 ratio to receive either the HH or TB appliance. Eligibility criteria included children aged 10-14 years with an overjet of ≥7 mm without dental anomalies. The primary outcome was the time (in months) required to reduce overjet to normal limits (<4 mm). Secondary outcomes included treatment failure rates, complications and their impact on oral health-related quality of life (OHRQOL). Randomization was accomplished using electronic software with allocation concealed using sequentially numbered, opaque, and sealed envelopes. Blinding was only applicable for outcome assessment. Data were analyzed using descriptive statistics and regression analyses to detect between-group differences, including Cox regression for time to treatment success. HH was significantly faster than TB in reducing the overjet to within normal limits (95% confidence interval [CI], -3.00 to -0.03; P = 0.046). Mean overjet reduction was more efficient with the HH than the TB appliance (ß = 1.3; 95% CI, 0.04-2.40; P = 0.04). Fifteen (37.5%) of the participants in the TB group and 7 (17.5%) in the HH group failed to complete the treatment (hazard ratio = 0.54; 95% CI, 0.32-0.91, P = 0.02). However, TB was associated with fewer routine (incidence rate ratio = 0.81; 95% CI, 0.7-0.9; P = 0.004) and emergency (incidence rate ratio = 0.1; 95% CI, 0.1-0.3; P = 0.001) visits. Chairside time was greater with the HH (ß = 2.7; 95% CI, 1.8-3.6, P = 0.001). Participants in both groups experienced complications with similar frequency. A greater deterioration in OHRQOL was found during treatment with the TB. Treatment with HH resulted in more efficient and predictable overjet reduction than TB. More treatment discontinuation and greater deterioration in OHRQOL were observed with the TB. However, HH was associated with more routine and emergency visits. ISRCTN11717011. The protocol was not published before trial commencement. No specific external or internal funding was provided. Treatment for participants was provided as part of routine orthodontic treatment in the hospital.

Identifiants

pubmed: 37409988
pii: S0889-5406(23)00314-1
doi: 10.1016/j.ajodo.2023.06.002
pii:
doi:

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

314-324.e1

Informations de copyright

Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved.

Auteurs

Moaiyad M Pacha (MM)

Centre for Oral Bioengineering, Institute of Dentistry, Queen Mary University of London, London, United Kingdom.

Padhraig S Fleming (PS)

Division of Public and Child Dental Health, Dublin Dental University Hospital, Trinity College Dublin, Dublin, Ireland.

Nikolas Pandis (N)

Department of Orthodontics and Dentofacial Orthopedics, Dental School/Medical Faculty, University of Bern, Bern, Switzerland.

Muftah Shagmani (M)

Department of Orthodontics, William Harvey Hospital, East Kent Hospitals University NHS Foundation Trust, Ashford, United Kingdom.

Ama Johal (A)

Centre for Oral Bioengineering, Institute of Dentistry, Queen Mary University of London, London, United Kingdom. Electronic address: a.s.johal@qmul.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH